Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.

Gao SG, Jia RN, Feng XS, Xie XH, Shan TY, Pan LX, Song NS, Wang YF, Ding KL, Wang LD.

World J Gastroenterol. 2011 Dec 21;17(47):5221-6. doi: 10.3748/wjg.v17.i47.5221.

PMID:
22215948
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.

Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ, Cho Sh, Kang MH, Go SI, Lee GW, Kim Hg, Kang JH.

Invest New Drugs. 2012 Feb;30(1):350-6. doi: 10.1007/s10637-010-9507-2. Epub 2010 Aug 13.

PMID:
20706861
[PubMed - indexed for MEDLINE]
3.

A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC.

Eur J Cancer. 2012 Mar;48(4):518-26. doi: 10.1016/j.ejca.2011.12.017. Epub 2012 Jan 12.

PMID:
22243774
[PubMed - indexed for MEDLINE]
4.

Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.

Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, Lu B, Wu C, Ju J.

PLoS One. 2011;6(8):e23271. doi: 10.1371/journal.pone.0023271. Epub 2011 Aug 18.

PMID:
21876743
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].

Zhou Y, Huang J, Yang L, Chi Y, Qu T, Lü X, Wang JW.

Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):860-4. doi: 10.3760/cma.j.issn.0253-3766.2012.11.014. Chinese.

PMID:
23291138
[PubMed - indexed for MEDLINE]
6.

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0. Epub 2013 Aug 28.

PMID:
23982118
[PubMed - indexed for MEDLINE]
7.

Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.

Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB.

Cancer Chemother Pharmacol. 2012 Aug;70(2):277-84. doi: 10.1007/s00280-012-1912-0. Epub 2012 Jun 30.

PMID:
22752217
[PubMed - indexed for MEDLINE]
8.

A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.

Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):985-90. doi: 10.1007/s00280-013-2278-7. Epub 2013 Sep 1.

PMID:
23995699
[PubMed - indexed for MEDLINE]
9.

Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.

Lee SJ, Cho SH, Yoon JY, Hwang JE, Bae WK, Shim HJ, Chung IJ.

Cancer Chemother Pharmacol. 2009 Dec;65(1):159-66. doi: 10.1007/s00280-009-1019-4. Epub 2009 May 29.

PMID:
19479256
[PubMed - indexed for MEDLINE]
10.

[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].

Zhao WY, Chen DY, Qi Q.

Zhonghua Zhong Liu Za Zhi. 2011 Apr;33(4):295-8. Chinese.

PMID:
21575503
[PubMed - indexed for MEDLINE]
11.

Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.

Cui Y, Li Q, Yu Y, Chen Y, Feng Y, Wang Y, Liu T.

Cancer Chemother Pharmacol. 2013 Jan;71(1):145-52. doi: 10.1007/s00280-012-1991-y. Epub 2012 Oct 12.

PMID:
23064955
[PubMed - indexed for MEDLINE]
12.

[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].

Yan D, Dai H.

Zhonghua Zhong Liu Za Zhi. 2009 Mar;31(3):217-9. Chinese.

PMID:
19615264
[PubMed - indexed for MEDLINE]
13.

Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.

Oh SY, Ju YT, Choi SK, Ha CY, Lee WS, Kim HG, Lee GW, Kwon HC, Kang JH.

Invest New Drugs. 2011 Oct;29(5):1050-6. doi: 10.1007/s10637-010-9409-3. Epub 2010 Mar 19.

PMID:
20238142
[PubMed - indexed for MEDLINE]
14.

Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.

Wang M, Wu M, Wang W, Wang Q, Wang Y.

Oncol Res Treat. 2014;37(1-2):24-8. doi: 10.1159/000358162. Epub 2014 Jan 24.

PMID:
24613905
[PubMed - indexed for MEDLINE]
15.

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y, Tsuburaya A.

Ann Oncol. 2010 May;21(5):1001-5. doi: 10.1093/annonc/mdp464. Epub 2009 Oct 29.

PMID:
19875759
[PubMed - indexed for MEDLINE]
Free Article
16.

Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.

Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK.

Ann Oncol. 2011 Apr;22(4):890-6. doi: 10.1093/annonc/mdq435. Epub 2010 Sep 22.

PMID:
20860988
[PubMed - indexed for MEDLINE]
Free Article
17.

Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.

Kang BW, Kim JG, Chae YS, Lee YJ, Lee SJ, Moon JH, Sohn SK, Jung MK, Jeon SW, Jang YJ, Seo J, Lee YH, Kwon O, Chung HY, Yu W.

Invest New Drugs. 2012 Aug;30(4):1671-5. doi: 10.1007/s10637-011-9729-y. Epub 2011 Aug 17.

PMID:
21845514
[PubMed - indexed for MEDLINE]
18.

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.

Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW.

Br J Cancer. 2011 Feb 15;104(4):605-12. doi: 10.1038/bjc.2011.17.

PMID:
21326246
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.

Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, Kim HJ, Jung HY, Lee GH, Kim KC, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2013 Oct;72(4):815-23. doi: 10.1007/s00280-013-2257-z. Epub 2013 Aug 7.

PMID:
23921575
[PubMed - indexed for MEDLINE]
20.

[Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].

Nishiwaki H, Yamada T, Tachi K, Iwasaki H, Hori Y, Umemura S, Yamakawa Y, Kurimoto T, Ban T, Fujiwara K, Hayashi K, Nemoto A, Shiroko J, Orito E.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1663-6. Japanese.

PMID:
19838024
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk